



Effective Date	Drug Name	Change Description	Reason Description	Alternate Drugs and Tier
1/1/2022	PAXIL 10 MG/5 ML ORAL SUSP	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PAROXETINE HCL 10 MG/5 ML ORAL SUSP-TIER 2
1/1/2022	AFINITOR DISPERZ 3 MG ORAL TAB SUSP	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 3 MG ORAL TAB SUSP-TIER 5
1/1/2022	AFINITOR DISPERZ 5 MG ORAL TAB SUSP	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 5 MG ORAL TAB SUSP-TIER 5
1/1/2022	AFINITOR 10 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 10 MG ORAL TABLET-TIER 5
1/1/2022	AFINITOR DISPERZ 2 MG ORAL TAB SUSP	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 2 MG ORAL TAB SUSP-TIER 5
3/1/2022	ZOSTAVAX 19400 UNIT SUBCUTANE. VIAL	REMOVAL DUE TO U.S. MARKET AVAILABILITY (NON SAFETY RELATED)	REMOVAL DUE TO U.S MARKET AVAILABILITY (NON-SAFETY RELATED)	
1/1/2022	DUREZOL 0.05 % OPHTHALMIC DROPS	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DIFLUPREDNATE 0.05 % OPHTHALMIC DROPS- TIER 2
1/1/2022	BYSTOLIC 5 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 5 MG ORAL TABLET-TIER 2

H9763_FCCREPORT_2002_C

Ochsner Health Plan is an HMO with a Medicare contract. Enrollment in Ochsner Health Plan depends on contract renewal.



1/1/2022	BYSTOLIC 10 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 10 MG ORAL TABLET-TIER 2
1/1/2022	CHANTIX 0.5 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VARENICLINE TARTRATE 0.5 MG ORAL TABLET- TIER 2
1/1/2022	CHANTIX 1 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VARENICLINE TARTRATE 1 MG ORAL TABLET- TIER 2
1/1/2022	BYSTOLIC 2.5 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 2.5 MG ORAL TABLET-TIER 2
1/1/2022	BYSTOLIC 20 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 20 MG ORAL TABLET-TIER 2